Target Evaluation & Molecular Therapeutics Group

I am a Postdoctoral Training Fellow interested in the study of the E3 ligase CUL4 CRBN and how to reprogram its function in the context of drug discovery.

I am a drug discovery biologist, specialising in the biology of B cell malignancies. I am working on gene regulation networks that control tumour plasticity and cell state, reprogramming cancer cells to commit to terminal differentiation or cell death using innovative compounds discovered at ICR.

I have worked at the ICR for over 15 years. I have worked on a number of drug discovery projects, including performing pre-clinical biological target validation for the CHK1 and AKT programmes; both of which produced clinical candidates. In my current work I have been pioneering molecular biology techniques to use as a tool for new drug target validation.

I am a Postdoctoral Training Fellow investigating DNA repair mechanisms and therapy resistance in estrogen positive breast cancers. My research at ICR is focused on developing therapy resistant breast cancer models, which will allow me to use a range of molecular and gene editing techniques to assess target contributions in the development of therapy resistance.

I joined the ICR in 2018 as the Executive Assistant to the CCDD Director and Head of the Cancer Therapeutics Division. I am very proud to be part of the ICR and the Centre for Cancer Drug Discovery. The Administrative team works very hard to provide the best support possible in an environment that encourages collaboration, the sharing of information and forward thinking. My daily aim is to provide the best support I can to the Head of Division and Unit so that they can focus on their science!

I am an experienced cell biologist funded by the Kidani trust to translate our team’s research into ovarian cancer models.

Katie joined the ICR in 2021 as a PhD student. She previously obtained her Bsc at The University of Sheffield and went on to work as a medicinal chemist at Redx Pharma for a year. She is currently working on converting existing small molecule inhibitors into degraders by identifying structural features that can lead to target degradation.